NATIONAL CANCER CENTER;OHARA PHARMACEUTICAL CO., LTD.
发明人:
SAKO MAGOICHI,TOSHIKAZU USHIJ1MA,NAOKO HATTORI
申请号：
US16607007
公开号：
US20200061093A1
申请日:
2018.04.24
申请国别(地区):
US
年份:
2020
代理人:
摘要：
[Problem]To provide, in place of injected agents (such as Vidaza® and Dacogen®) clinically used as therapeutic drugs for high-risk myelodysplastic syndromes, a medicine as a therapeutic drug or a prophylactic drug for various advanced solid tumors, said medicine having high stability with respect to cytidine deaminase which is a hydrolytic metabolic enzyme, being absorbed into the body even by oral administration, and having an effect of being integrated into a nucleic acid biosynthetic route and inhibiting DNA methyltransferases, i.e., DNMTs.[Solution]The aforementioned problem is solved by a novel compound represented by formula (I). (In the formula, R is a hydroxyl group or a hydrogen atom, and R1 and R2 are each a benzyl group that may have a substituent.)
